Aqua Bio Technology — Share Issue/Capital Change 2026

Mar 12, 2026

Aqua Bio Technology ASA: Subsequent Offering Start of Subscription Period

Aqua Bio Technology ASA: Subsequent Offering Start of Subscription Period

NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION, IN WHOLE OR IN PART DIRECTLY OR

INDIRECTLY, IN AUSTRALIA, CANADA, JAPAN, HONG KONG, SOUTH AFRICA OR THE UNITED

STATES OR ANY OTHER JURISDICTION IN WHICH THE RELEASE, PUBLICATION OR

DISTRIBUTION WOULD BE UNLAWFUL. THIS ANNOUNCEMENT DOES NOT CONSTITUTE AN OFFER

OF ANY OF THE SECURITIES DESCRIBED HEREIN

Reference is made to the stock exchange announcement by Aqua Bio Technology

ASA ("ABTEC" or the "Company") on 11 March 2026 regarding the terms of a

subsequent offering of new shares in the Company (the "Subsequent Offering").

The Subsequent Offering consists of an offering of up to 800,000 new shares in

the Company (the "Offer Shares") directed towards the shareholders of the

Company as of 12 February 2026 (as registered in the VPS on 16 February 2026)

(the "Record Date"), except: (i) shareholders who were allocated shares in the

Private Placement, and (ii) shareholders who are resident in a jurisdiction

where such offering would be unlawful, or would require any prospectus filing,

registration or similar action (the "Eligible Shareholders"). The subscription

price per Offer Share is NOK 5.00 (the "Subscription Price").

In addition, the following types of investors shall have a secondary right to

subscribe for the Offer Shares: (i) ABTEC shareholders and other investors who

participated in the Private Placement, and (ii) other subscribers without

Subscription Rights (jointly, the "Secondary Subscribers") subject to a

minimum allocation of NOK 50,000. The Secondary Subscribers may subscribe for

Offer Shares that have not been subscribed and allocated to Eligible

Shareholders.

The Eligible Shareholders will be granted 0.0103 non-tradable subscription

rights to be used for subscription of Offer Shares (the "Subscription Rights")

for each existing share registered as held by such Eligible Shareholder as of

the Record Date, rounded down to the nearest whole number of Subscription

Rights. The number of Subscription Rights granted has been calculated based on

the number of shares outstanding in the Company prior to completion of the

reverse share split completed in February 2026. Each whole Subscription Right

provides a preferential right to subscribe for, and be allocated, one Offer

Share at the Subscription Price.

Over-subscription will be permitted.

Subscription without Subscription Rights will not be permitted, other than by

Secondary Subscribers.

The subscription period in the Subsequent Offering commences today, on 12

March 2026 at 09:00 hours (CET) and will end on 19 March 2026 at 16:30 hours

(CET). Subscription Rights that are not used to subscribe for Offer Shares

before 16:30 hours (CET) on 19 March 2026 will have no value and will lapse

without compensation to the holder.

An invitation letter (the "Invitation Letter") has been prepared in connection

with the Subsequent Offering, which sets out the terms and conditions for the

Subsequent Offering and includes a description of certain risk factors

pertaining to the Company, its shares and the Subsequent Offering.

Subscriptions by Eligible Shareholders may be made through the VPS' online

subscription system, or by correctly completing and signing the subscription

form included in the Invitation Letter. Eligible Shareholders who are

residents of Norway with a Norwegian national identity number, and Norwegian

private/public limited companies (AS/ASA), may be made electronically through

an online subscription system through a link available on the Company's

website https://aquabiotechnology.com/press-releases/. Subscription Rights

that are not used to subscribe for Offer Shares before the expiry of the

subscription period will have no value and will lapse without compensation to

the holder.

The Invitation Letter is attached hereto and will also be made available at

websites of the Company, on www.aquabiotechnology.com. Further information on

the Subsequent Offering is also available from the Company's stock exchange

notice dated 11 March 2026.

IMPORTANT INFORMATION

This announcement is not an offer to sell or a solicitation of offers to

purchase or subscribe for shares. Copies of this announcement may not be sent

to jurisdictions, or distributed in or sent from jurisdictions, in which this

is barred or prohibited by law. The information contained herein shall not

constitute an offer to sell or the solicitation of an offer to buy, in any

jurisdiction in which such offer or solicitation would be unlawful absent

registration, or an exemption from registration or qualification under the

securities laws of any jurisdiction.

This document is not for publication or distribution in, directly or

indirectly, Australia, Canada, Japan, Hong Kong or the United States or any

other jurisdiction in which such release, publication or distribution would be

unlawful, and it does not constitute an offer or invitation to subscribe for

or purchase any securities in such countries or in any other jurisdiction. In

particular, the document and the information contained herein should not be

distributed or otherwise transmitted into the United States or to publications

with a general circulation in the United States of America.

This announcement is not an offer for sale of securities in the United States.

Securities may not be offered or sold in the United States absent registration

with the United States Securities and Exchange Commission or an exemption from

registration under the U.S. Securities Act of 1933, as amended (the

"Securities Act"). The Company does not intend to register any part of the

offering in the United States or to conduct a public offering in the United

States of the shares to which this document relates. This announcement is for

information purposes only and is not to be relied upon in substitution for the

exercise of independent judgment. It is not intended as investment advice and

under no circumstances is it to be used or considered as an offer to sell, or

a solicitation of an offer to buy any securities or a recommendation to buy or

sell any securities of the Company.

This announcement and any materials distributed in connection with this

announcement may contain certain forward-looking statements. By their nature,

forward-looking statements involve risk and uncertainty because they reflect

current expectations and assumptions as to future events and circumstances

that may not prove accurate. A number of material factors could cause actual

results and developments to differ materially from those expressed or implied

by these forward-looking statements.

The Company expressly disclaims any obligation or undertaking to update,

review or revise any statement contained in this announcement whether as a

result of new information, future developments or otherwise.

Contacts

Kristian Flaten

CEO & CFO

Aqua Bio Technology ASA

Phone: +47 9509 2322

Email: kf@aquabiotech.no

About Us

Aqua Bio Technology ASA (ABTEC) is a technology and distribution group in

skincare and nonfood. The group has distribution towards B2C and B2B, and

offers freight, customs, and logistics services. The group also develops

sustainable biotechnology for use in skincare products. Aqua Bio Technology is

listed on Euronext Expand Oslo.

This notice is published by Kristian Flaten on the listed date and time.

This information has been submitted pursuant to the Securities Trading Act §

5-12 and MAR. The information was submitted for publication, through the

agency of the contact persons set out above, at 2026-03-12 07:45 CET.